{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:19:06Z","timestamp":1790716746194,"version":"4.1.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The objectives of this study were to elicit the preferences of patients with multiple myeloma regarding the possible benefits and risks of cancer treatments and to illustrate how such data may be used to estimate patients\u2019 acceptance of new treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patients with multiple myeloma from the cancer charity Myeloma UK were invited to participate in an online survey based on multicriteria decision analysis and swing weighting to elicit individual stated preferences for the following attributes: (a) 1-year progression-free survival (PFS, ranging from 50% to 90%), (b) mild or moderate toxicity for 2 months or longer (ranging from 85% to 45%), and (c) severe or life-threatening toxicity (ranging from 80% to 20%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 560 participants completed the survey. The average weight given to PFS was 0.54, followed by 0.32 for severe or life-threatening toxicity and 0.14 for mild or moderate chronic toxicity. Participants who ranked severe or life-threatening toxicity above mild or moderate chronic toxicity (56%) were more frequently younger, working, and looking after dependent family members and had more frequently experienced severe or life-threatening side effects. The amount of weight given to PFS did not depend on any of the collected covariates. The feasibility of using the collected preference data to estimate the patients\u2019 acceptance of specific multiple myeloma treatments was demonstrated in a subsequent decision analysis example.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Stated preference studies provide a systematic approach to gain knowledge about the distribution of preferences in the population and about what this implies for patients\u2019 acceptance of specific treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>This study demonstrated how quantitative preference statements from a large group of participants can be collected through an online survey and how such information may be used to explore the acceptability of specific treatments based on the attributes studied. Results from such studies have the potential to become an important new tool for gathering patient views and studying heterogeneity in preferences in a systematic way, along with other methods, such as focus groups and expert opinions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0257","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T18:30:19Z","timestamp":1509129019000},"page":"44-51","source":"Crossref","is-referenced-by-count":59,"title":["Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma"],"prefix":"10.1093","volume":"23","author":[{"given":"Douwe","family":"Postmus","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"European Medicines Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Richard","sequence":"additional","affiliation":[{"name":"Myeloma UK, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bere","sequence":"additional","affiliation":[{"name":"European Medicines Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"van Valkenhoef","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Galinsky","sequence":"additional","affiliation":[{"name":"Myeloma UK, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Low","sequence":"additional","affiliation":[{"name":"Myeloma UK, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Moulon","sequence":"additional","affiliation":[{"name":"European Medicines Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mavris","sequence":"additional","affiliation":[{"name":"European Medicines Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Salmonsson","sequence":"additional","affiliation":[{"name":"European Medicines Agency, London, United Kingdom"},{"name":"L\u00e4kemedelsverket Medical Products Agency, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Flores","sequence":"additional","affiliation":[{"name":"Medicines & Healthcare products Regulatory Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hillege","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pignatti","sequence":"additional","affiliation":[{"name":"European Medicines Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"2021122509422714200_onco12297-bib-0001","author":"Medical Device Innovation Consortium","year":"2017"},{"key":"2021122509422714200_onco12297-bib-0002","author":"European Medicines Agency","year":"2017"},{"key":"2021122509422714200_onco12297-bib-0003","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cpt.332","article-title":"Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators","volume":"99","author":"Postmus","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2021122509422714200_onco12297-bib-0004","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/sim.4194","article-title":"A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis","volume":"30","author":"Tervonen","year":"2011","journal-title":"Stat Med"},{"key":"2021122509422714200_onco12297-bib-0005","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122509422714200_onco12297-bib-0006","article-title":"Evaluating patients\u2019 preferences for multiple myeloma therapy, a Discrete-Choice-Experiment","author":"M\u00fchlbacher","year":"2008","journal-title":"Psychosoc Med"},{"key":"2021122509422714200_onco12297-bib-0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2015.11.006","article-title":"Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis","volume":"40","author":"Landfeldt","year":"2016","journal-title":"Leuk Res"},{"key":"2021122509422714200_onco12297-bib-0008","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0269216315578803","article-title":"Comparison of preferences for end-of-life care among patients with advanced cancer and their caregivers: A discrete choice experiment","volume":"29","author":"Malhotra","year":"2015","journal-title":"Palliat Med"},{"key":"2021122509422714200_onco12297-bib-0009","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/0272989X15587005","article-title":"Applying multiple criteria decision analysis to comparative benefit-risk assessment: Choosing among statins","volume":"35","author":"Tervonen","year":"2015","journal-title":"in primary prevention. Med Decis Making"},{"key":"2021122509422714200_onco12297-bib-0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/CBO9780511611308.020","volume-title":"Advances in Decision Analysis: From Foundations to Applications","author":"Phillips","year":"2007"},{"key":"2021122509422714200_onco12297-bib-0011","author":"Postmus","year":"2017"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0257","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0257","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/1\/44\/41914619\/oncolo_23_1_44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/1\/44\/41914619\/oncolo_23_1_44.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T09:42:57Z","timestamp":1640425377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/1\/44\/6438708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,10,27]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0257","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1,1]]},"published":{"date-parts":[[2017,10,27]]}}}